December 2025 in “Molecules” This study found that the 15-PGDH inhibitor DPP improved endothelial function in hair-related cells exposed to DHT by reducing oxidative stress and enhancing angiogenic capacity.
April 2026 in “Cosmetics” In this randomized, double-blind, placebo-controlled trial, researchers found that a multi-targeted cosmetic formulation containing TrinogeniX™ significantly increased hair density and thickness in individuals with androgenetic alopecia without adverse effects, suggesting it as a potential safe and effective treatment option.
July 2024 in “International Journal of Molecular Sciences” This study explored the effects of DPP, a 15-PGDH inhibitor, on human follicle dermal papilla cells damaged by dihydrotestosterone and observed that DPP enhanced wound healing, reduced reactive oxygen species, and increased hair growth in ex vivo human hair follicle cultures.
December 2025 in “Biomolecules” In this study, the synthesis and testing of new pyrroloquinoline derivatives identified compound 7p, which showed low micromolar cytotoxic activity against MCF-7 and HeLa cells, highlighting its potential for development into a potent anticancer agent.